SpringerLink
Log in

Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

The spectrum of BRCA1/2 mutations demonstrates significant interethnic variations. We analyzed for the first time the entire BRCA1/2 coding region in 340 Belarusian cancer patients with clinical signs of BRCA1/2-related disease, including 168 women with bilateral and/or early-onset breast cancer (BC), 104 patients with ovarian cancer and 68 subjects with multiple primary malignancies involving BC and/or OC. BRCA1/2 pathogenic alleles were detected in 98 (29%) women, with 67 (68%) of these being represented by founder alleles. Systematic comparison with other relevant studies revealed that the founder effect observed in Belarus is among the highest estimates observed worldwide. These findings are surprising, given that the population of Belarus did not experience geographic or cultural isolation throughout history.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  1. Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC (2021) Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study. Front Oncol 10:619469. https://doi.org/10.3389/fonc.2020.619469

    Article  Google Scholar 

  2. Van den Eynden J, Descamps T, Delporte E, Roosens NHC, De Keersmaecker SCJ, De Wit V, Vermeesch JR, Goetghebeur E, Tafforeau J, Demarest S, Van den Bulcke M, Van Oyen H (2018) The genetic structure of the Belgian population. Hum Genomics 12:6. https://doi.org/10.1186/s40246-018-0136-8

    Article  Google Scholar 

  3. Konstantopoulou I, Tsitlaidou M, Fostira F, Pertesi M, Stavropoulou AV, Triantafyllidou O, Tsotra E, Tsiftsoglou AP, Tsionou C, Droufakou S, Dimitrakakis C, Fountzilas G, Yannoukakos D (2014) High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. Clin Genet 85:36–42. https://doi.org/10.1111/cge.12274

    Article  CAS  Google Scholar 

  4. Sulem P, Helgason H, Oddson A, Stefansson H, Gudjonsson SA, Zink F, Hjartarson E, Sigurdsson GT, Jonasdottir A, Jonasdottir A, Sigurdsson A, Magnusson OT, Kong A, Helgason A, Holm H, Thorsteinsdottir U, Masson G, Gudbjartsson DF, Stefansson K (2015) Identification of a large set of rare complete human knockouts. Nat Genet 47:448–452. https://doi.org/10.1038/ng.3243

    Article  CAS  Google Scholar 

  5. Janavičius R, Rudaitis V, Mickys U, Elsakov P, Griškevičius L (2014) Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet 207:195–205. https://doi.org/10.1016/j.cancergen.2014.05.002

    Article  CAS  Google Scholar 

  6. Sokolenko AP, Sokolova TN, Ni VI, Preobrazhenskaya EV, Iyevleva AG, Aleksakhina SN, Romanko AA, Bessonov AA, Gorodnova TV, Anisimova EI, Savonevich EL, Bizin IV, Stepanov IA, Krivorotko PV, Berlev IV, Belyaev AM, Togo AV, Imyanitov EN (2020) Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Res Treat 184:229–235. https://doi.org/10.1007/s10549-020-05827-8

    Article  CAS  Google Scholar 

  7. Savanevich A, Oszurek O, Lubiński J, Cybulski C, Dębniak T, Narod SA, Gronwald J (2014) BRCA1 founder mutations compared to ovarian cancer in Belarus. Fam Cancer 13:445–447. https://doi.org/10.1007/s10689-014-9721-8

    Article  CAS  Google Scholar 

  8. Savanevich A, Ashuryk O, Cybulski C, Lubiński J, Gronwald J (2021) BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update. Hered Cancer Clin Pract 19:13. https://doi.org/10.1186/s13053-021-00169-y

    Article  CAS  Google Scholar 

  9. Preobrazhenskaya EV, Shleykina AU, Gorustovich OA, Martianov AS, Bizin IV, Anisimova EI, Sokolova TN, Chuinyshena SA, Kuligina ES, Togo AV, Belyaev AM, Ivantsov AO, Sokolenko AP, Imyanitov EN (2021) Frequency and molecular characteristics of PALB2-associated cancers in Russian patients. Int J Cancer 148:203–210. https://doi.org/10.1002/ijc.33317

    Article  CAS  Google Scholar 

  10. Bu H, Chen J, Li Q, Hou J, Wei Y, Yang X, Ma Y, He H, Zhang Y, Kong B (2019) BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group. J Obstet Gynaecol Res 45:2267–2274. https://doi.org/10.1111/jog.14090

    Article  CAS  Google Scholar 

  11. Gupta S, Rajappa S, Advani S, Agarwal A, Aggarwal S, Goswami C, Palanki SD, Arya D, Patil S, Kodagali R (2021) Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study. JCO Glob Oncol 7:849–861. https://doi.org/10.1200/GO.21.00051

    Article  Google Scholar 

  12. Stegel V, Blatnik A, Škof E, Dragoš V, Krajc M, Gregorič B, Škerl P, Strojnik K, Klančar G, Banjac M, Žgajnar J, Ravnik M, Novaković S (2022) Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing. Cancers (Basel) 14:1434. https://doi.org/10.3390/cancers14061434

    Article  CAS  Google Scholar 

  13. Van der Merwe NC, van Rensburg EJ (2009) Hereditary breast/ovarian cancer and BRCA mutations: A South African perspective. Abstract, Third International Symposium on Hereditary Breast and Ovarian Cancer. Quebec, Canada 14–16 October 2009. Current Oncology 16:91–110

  14. Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van Rensburg EJ (2004) BRCA1 mutations in South African breast and/or ovarian cancer families: evidence of a novel founder mutation in Afrikaner families. Int J Cancer 110:677–682. https://doi.org/10.1002/ijc.20186

    Article  CAS  Google Scholar 

  15. Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, King MC (2017) Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncol 3:1647–1653. https://doi.org/10.1001/jamaoncol.2017.1996

    Article  Google Scholar 

  16. Laitman Y, Feng BJ, Zamir IM, Weitzel JN, Duncan P, Port D, Thirthagiri E, Teo SH, Evans G, Latif A, Newman WG, Gershoni-Baruch R, Zidan J, Shimon-Paluch S, Goldgar D, Friedman E (2013) Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. Eur J Hum Genet 21:212–216. https://doi.org/10.1038/ejhg.2012.124

    Article  CAS  Google Scholar 

  17. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King MC, Ponder BA, Weber B, Devilee P, Borg A, Narod SA, Goldgar D (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62:1381–1388. https://doi.org/10.1086/301885

    Article  CAS  Google Scholar 

  18. Slatkin M (2004) A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am J Hum Genet 75:282–293. https://doi.org/10.1086/423146

    Article  CAS  Google Scholar 

  19. Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, Kalis ML, Peretz T, Shohat M, Basel-Salmon L, Friedman E, Bazak L, Goldberg Y (2018) The yield of full BRCA1/2 genoty** in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Res Treat 172:151–157. https://doi.org/10.1007/s10549-018-4887-7

    Article  CAS  Google Scholar 

  20. Solano AR, Liria NC, Jalil FS, Faggionato DM, Mele PG, Mampel A, Cardoso FC, Podesta EJ (2018) BRCA1 and BRCA2 Mutations Other Than the Founder Alleles Among Ashkenazi Jewish in the Population of Argentina. Front Oncol 8:323. https://doi.org/10.3389/fonc.2018.00323

    Article  Google Scholar 

  21. Bernstein-Molho R, Laitman Y, Schayek H, Reish O, Lotan S, Haim S, Zidan J, Friedman E (2017) The yield of targeted genoty** for the recurring mutations in BRCA1/2 in Israel. Breast Cancer Res Treat 167:697–702. https://doi.org/10.1007/s10549-017-4551-7

    Article  CAS  Google Scholar 

  22. Nielsen SM, De Simone LM, Olopade OI (2018) Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns 27:1405–1410. https://doi.org/10.1007/s10897-018-0269-x

    Article  Google Scholar 

  23. Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E (2020) Population Screening for Inherited Predisposition to Breast and Ovarian Cancer. Annu Rev Genomics Hum Genet 21:373–412. https://doi.org/10.1146/annurev-genom-083118-015253

    Article  CAS  Google Scholar 

  24. Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, Zhang S, Narod SA, Hurley J (2014) The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 85:64–67. https://doi.org/10.1111/cge.12132

    Article  CAS  Google Scholar 

  25. Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, Niu Q, Huo D, Sveen WE, Ogundiran T, Adebamowo C, Odetunde A, Falusi AG, Olopade OI (2012) High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer 131:1114–1123. https://doi.org/10.1002/ijc.27326

    Article  CAS  Google Scholar 

  26. Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Francis W, Halliday D, Royer R, Zhang S, Li S, Thompson I, Donenberg T, Hurley J, Akbari MR, Narod SA (2016) Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clin Genet 89:328–331. https://doi.org/10.1111/cge.12602

    Article  CAS  Google Scholar 

  27. George SHL, Donenberg T, Alexis C, DeGennaro V Jr, Dyer H, Yin S, Ali J, Butler R, Chin SN, Curling D, Lowe D, Lunn J, Turnquest T, Wharfe G, Cerbon D, Barreto-Coelho P, Schlumbrecht MP, Akbari MR, Narod SA, Hurley JE (2021) Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean. JAMA Netw Open 4:e210307. https://doi.org/10.1001/jamanetworkopen.2021.0307

    Article  Google Scholar 

  28. Claes K, Poppe B, Coene I, Paepe AD, Messiaen L (2004) BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer 90:1244–1251. https://doi.org/10.1038/sj.bjc.6601656

    Article  CAS  Google Scholar 

  29. Alvarez C, Tapia T, Perez-Moreno E, Gajardo-Meneses P, Ruiz C, Rios M, Missarelli C, Silva M, Cruz A, Matamala L, Carvajal-Carmona L, Camus M, Carvallo P (2017) BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget 8:74233–74243. https://doi.org/10.18632/oncotarget.18815

    Article  Google Scholar 

  30. Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H (1997) Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6:2309–2315. https://doi.org/10.1093/hmg/6.13.2309

    Article  CAS  Google Scholar 

  31. Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H (2001) BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 9:424–430. https://doi.org/10.1038/sj.ejhg.5200652

    Article  CAS  Google Scholar 

  32. Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL (2011) Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res 13:R20. https://doi.org/10.1186/bcr2832

    Article  CAS  Google Scholar 

  33. Kääriäinen H, Muilu J, Perola M, Kristiansson K (2017) Genetics in an isolated population like Finland: a different basis for genomic medicine? J Community Genet 8:319–326. https://doi.org/10.1007/s12687-017-0318-4

    Article  Google Scholar 

  34. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, Sinilnikova O, Tihomirova L, Lubinski J, Gronwald J, Gorski B, Hansen Tv, Nielsen FC, Thomassen M, Yannoukakos D, Konstantopoulou I, Zajac V, Ciernikova S, Couch FJ, Greenwood CM, Goldgar DE, Foulkes WD (2011) On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 19:300–306. https://doi.org/10.1038/ejhg.2010.203

    Article  Google Scholar 

  35. Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E (2020) BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. Int J Cancer 147:1334–1342. https://doi.org/10.1002/ijc.32903

    Article  CAS  Google Scholar 

  36. Pertesi M, Konstantopoulou I, Yannoukakos D (2011) Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population. Clin Genet 80:375–382. https://doi.org/10.1111/j.1399-0004.2010.01532.x

    Article  CAS  Google Scholar 

  37. Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, Athanasiou A, Dobrovic A, Young MA, Goldgar D, Fountzilas G, Yannoukakos D (2008) G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Res Treat 110:377–385. https://doi.org/10.1007/s10549-007-9729-y

    Article  CAS  Google Scholar 

  38. Hansen TV, Ejlertsen B, Albrechtsen A, Bergsten E, Bjerregaard P, Hansen T, Myrhøj T, Nielsen PB, Timmermans-Wielenga V, Andersen MK, Jønson L, Nielsen FC (2009) A common Greenlandic Inuit BRCA1 RING domain founder mutation. Breast Cancer Res Treat 115:69–76. https://doi.org/10.1007/s10549-008-0060-z

    Article  CAS  Google Scholar 

  39. Harboe TL, Eiberg H, Kern P, Ejlertsen B, Nedergaard L, Timmermans-Wielenga V, Nielsen IM, Bisgaard ML (2009) A high frequent BRCA1 founder mutation identified in the Greenlandic population. Fam Cancer 8:413–419. https://doi.org/10.1007/s10689-009-9257-5

    Article  CAS  Google Scholar 

  40. Hansen TV, Jønson L, Albrechtsen A, Steffensen AY, Bergsten E, Myrhøj T, Ejlertsen B, Nielsen FC (2010) Identification of a novel BRCA1 nucleotide 4803delCC/c.4684delCC mutation and a nucleotide 249T > A/c.130T > A (p.Cys44Ser) mutation in two Greenlandic Inuit families: implications for genetic screening of Greenlandic Inuit families with high risk for breast and/or ovarian cancer. Breast Cancer Res Treat 124:259–264. https://doi.org/10.1007/s10549-010-0909-9

    Article  CAS  Google Scholar 

  41. Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B, Pulay T, Toth J, Devilee P, King MC, Olah E (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86:737–740. https://doi.org/10.1002/(sici)1097-0215(20000601)86:53.0.co;2-1

    Article  Google Scholar 

  42. Kaufman B, Laitman Y, Gronwald J, Lubinski J, Friedman E (2009) Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals. Genet Test Mol Biomarkers 13:465–469. https://doi.org/10.1089/gtmb.2009.0001

    Article  CAS  Google Scholar 

  43. Papp J, Kovacs ME, Matrai Z, Orosz E, Kásler M, Børresen-Dale AL, Olah E (2016) Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary. Fam Cancer 15:85–97. https://doi.org/10.1007/s10689-015-9845-5

    Article  CAS  Google Scholar 

  44. Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir A, Steingrimsson E, Thorlacius S (2004) BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer 40:2788–2793. https://doi.org/ 10.1016/j.ejca.2004.09.008

  45. Ebenesersdóttir SS, Sandoval-Velasco M, Gunnarsdóttir ED, Jagadeesan A, Guðmundsdóttir VB, Thordardóttir EL, Einarsdóttir MS, Moore KHS, Sigurðsson Á, Magnúsdóttir DN, Jónsson H, Snorradóttir S, Hovig E, Møller P, Kockum I, Olsson T, Alfredsson L, Hansen TF, Werge T, Cavalleri GL, Gilbert E, Lalueza-Fox C, Walser JW 3rd, Kristjánsdóttir S, Gopalakrishnan S, Árnadóttir L, Magnússon ÓÞ, Gilbert MTP, Stefánsson K, Helgason A (2018) Ancient genomes from Iceland reveal the making of a human population. Science 360:1028–1032. https://doi.org/10.1126/science.aar2625

    Article  CAS  Google Scholar 

  46. Janavičius R, Rudaitis V, Feng BJ, Ozolina S, Griškevičius L, Goldgar D, Tihomirova L (2013) Haplotype analysis and ancient origin of the BRCA1 c.4035delA Baltic founder mutation. Eur J Med Genet 56:125–130. https://doi.org/10.1016/j.ejmg.2012.12.007

    Article  Google Scholar 

  47. Kushniarevich A, Utevska O, Chuhryaeva M, Agdzhoyan A, Dibirova K, Uktveryte I, Möls M, Mulahasanovic L, Pshenichnov A, Frolova S, Shanko A, Metspalu E, Reidla M, Tambets K, Tamm E, Koshel S, Zaporozhchenko V, Atramentova L, Kučinskas V, Davydenko O, Goncharova O, Evseeva I, Churnosov M, Pocheshchova E, Yunusbayev B, Khusnutdinova E, Marjanović D, Rudan P, Rootsi S, Yankovsky N, Endicott P, Kassian A, Dybo A, Genographic Consortium, Tyler-Smith C, Balanovska E, Metspalu M, Kivisild T, Villems R, Balanovsky O (2015) Genetic Heritage of the Balto-Slavic Speaking Populations: A Synthesis of Autosomal, Mitochondrial and Y-Chromosomal Data. PLoS ONE 10:e0135820. https://doi.org/10.1371/journal.pone.0135820

    Article  CAS  Google Scholar 

  48. ElBiad O, Laraqui A, El Boukhrissi F, Mounjid C, Lamsisi M, Bajjou T, Elannaz H, Lahlou AI, Kouach J, Benchekroune K, Oukabli M, Chahdi H, Ennaji MM, Tanz R, Sbitti Y, Ichou M, Ennibi K, Badaoui B, Sekhsokh Y (2022) Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. BMC Cancer 22:208. https://doi.org/10.1186/s12885-022-09181-4

    Article  CAS  Google Scholar 

  49. Charoute H, Bakhchane A, Benrahma H, Romdhane L, Gabi K, Rouba H, Fakiri M, Abdelhak S, Lenaers G, Barakat A (2015) Mediterranean Founder Mutation Database (MFMD): Taking Advantage from Founder Mutations in Genetics Diagnosis, Genetic Diversity and Migration History of the Mediterranean Population. Hum Mutat 36:E2441–E2453. https://doi.org/10.1002/humu.22835

    Article  CAS  Google Scholar 

  50. Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L (2018) BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway. Hered Cancer Clin Pract 16:3. https://doi.org/10.1186/s13053-017-0085-6

    Article  Google Scholar 

  51. Rudkin TM, Hamel N, Galvez M, Hogervorst F, Gille JJ, Møller P, Apold J, Foulkes WD (2006) The frequent BRCA1 mutation 1135insA has multiple origins: a haplotype study in different populations. BMC Med Genet 7:15. https://doi.org/10.1186/1471-2350-7-15

    Article  Google Scholar 

  52. Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A (2007) Genetic epidemiology of BRCA mutations–family history detects less than 50% of the mutation carriers. Eur J Cancer 43:1713–1717. https://doi.org/10.1016/j.ejca.2007.04.023

    Article  Google Scholar 

  53. Diaz-Zabala HJ, Ortiz AP, Garland L, Jones K, Perez CM, Mora E, Arroyo N, Oleksyk TK, Echenique M, Matta JL, Dean M, Dutil J (2018) A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico. Cancers (Basel) 10:419. https://doi.org/10.3390/cancers10110419

    Article  CAS  Google Scholar 

  54. Ndiaye R, Diop JPD, Bourdon-Huguenin V, Dem A, Diouf D, Dieng MM, Diop PS, Kane Gueye SM, Ba SA, Dia Y, Ka S, Mbengue B, Thiam A, Sylla Niang M, Gueye PM, Faye O, Lopez Sall P, Cisse A, Diop PA, Sobol H, Dieye A (2020) Evidence for an ancient BRCA1 pathogenic variant in inherited breast cancer patients from Senegal. NPJ Genom Med 5:8. https://doi.org/10.1038/s41525-020-0114-7

    Article  CAS  Google Scholar 

  55. Mefford HC, Baumbach L, Panguluri RC, Whitfield-Broome C, Szabo C, Smith S, King MC, Dunston G, Stoppa-Lyonnet D, Arena F (1999) Evidence for a BRCA1 founder mutation in families of West African ancestry. Am J Hum Genet 65:575–578. https://doi.org/10.1086/302511

    Article  CAS  Google Scholar 

  56. Blanc M, Sanchez-Mazas A, Van Blyenburgh NH, Sevin A, Pison G, Langaney A (1990) Interethnic genetic differentiation: GM polymorphism in eastern Senegal. Am J Hum Genet 46:383–392

    CAS  Google Scholar 

  57. Fitzpatrick MB, Rendi MH, Kiviat NB, Toure P, Dem A, Sow PS, Hawes SE, Feng Q, Allison KH (2019) Pathology of Senegalese breast cancers. Pan Afr Med J 34:67. https://doi.org/10.11604/pamj.2019.34.67.17993

    Article  Google Scholar 

  58. Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, Stempa K, Gronwald J, Szymiczek A, Bagherzadeh M, Jakubowska A, Dębniak T, Lener M, Rudnicka H, Szwiec M, Jarkiewicz-Tretyn J, Stawicka M, Domagała P, Narod SA, Lubiński J, Akbari MR, Polish Hereditary Breast Cancer Consortium (2019) The spectrum of mutations predisposing to familial breast cancer in Poland. Int J Cancer 145:3311–3320. https://doi.org/10.1002/ijc.32492

    Article  CAS  Google Scholar 

  59. Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, Hadjieva MST, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP (2015) Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer 15:523. https://doi.org/10.1186/s12885-015-1516-2

    Article  Google Scholar 

  60. Machackova E, Claes K, Mikova M, Házová J, Sťahlová EH, Vasickova P, Trbusek M, Navrátilová M, Svoboda M, Foretová L (2019) Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants. Klin Onkol 32(Supplementum2):51–71. https://doi.org/10.14735/amko2019S51

    Google Scholar 

  61. Krivokuca A, Mihajlovic M, Susnjar S, Spasojevic IB, Minic I, Popovic L, Brankovic-Magic M (2021) Mutational profile of hereditary breast and ovarian cancer - Establishing genetic testing guidelines in a develo** country. Curr Probl Cancer 10:100767. https://doi.org/10.1016/j.currproblcancer.2021.100767

    Google Scholar 

Download references

Funding

The study was supported by the Russian Foundation for Basic Research [grant number 20-515-00002] and Belarusian Republican Foundation for Basic Research [grant number M20P-40].

Author information

Authors and Affiliations

  1. Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Saint-Petersburg, Russia

    G. A. Yanus, A. P. Sokolenko, A. A. Romanko, V. I. Ni, E. Kh. Bakaeva, I. V. Bizin & E. N. Imyanitov

  2. Department of Obstetrics and Gynecology, Grodno State Medical University, Grodno, Belarus

    E. L. Savonevich & O. A. Gorustovich

  3. Department of Medical Genetics, St.-Petersburg Pediatric Medical University, Saint-Petersburg, Russia

    A. P. Sokolenko, A. A. Romanko & E. N. Imyanitov

  4. Department of Oncology, I.I. Mechnikov North-Western Medical University, St.-Petersburg, Russia

    E. N. Imyanitov

Authors
  1. G. A. Yanus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. L. Savonevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. P. Sokolenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. A. Romanko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. I. Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Kh. Bakaeva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. O. A. Gorustovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. I. V. Bizin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. N. Imyanitov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. P. Sokolenko.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

The study design was approved by the local Ethical Committee. All procedures performed in study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yanus, G.A., Savonevich, E.L., Sokolenko, A.P. et al. Founder vs. non-founder BRCA1/2 pathogenic alleles: the analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations. Familial Cancer 22, 19–30 (2023). https://doi.org/10.1007/s10689-022-00296-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-022-00296-y

Keywords

Search

Navigation